Business
Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action
Dr. Stephen J. Nicholls joins as guest speaker TSX Exchange Symbol: RVX CALGARY...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n\n\nDr. Stephen J. Nicholls joins as guest speaker\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, April 19, 2012 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the\n \"Company\") (TSX: RVX) is pleased to announce for the first time the\n \"Mechanism of Action\" (MoA) by which RVX-208 increases apolipoprotein\n A-I (ApoA-I) production. Please join us via Conference Call & Webcast\n on Monday, April 23, 2012, commencing at 11 am EDT. Dr. Stephen J. Nicholls, Heart Disease Theme Leader at the South\n Australian Health and Medical Research Institute, will join\n Resverlogix' President and Chief Executive Officer Donald McCaffrey and\n Chief Scientific Officer Dr. Norman Wong for an in-depth presentation.\n\n\nLink to access the Webcast:http://services.choruscall.com/links/resverlogix120423.html\n\n\nConference call dial-in numbers:\n\n\nCanada & USA Toll Free Dial In:  \n\n\n \n\n\n \n\n\n1-800-319-4610\n\n\nOutside of Canada & USA call:\n\n\n \n\n\n \n\n\n+1-604-638-5340\n\n\nIn other news, Resverlogix is pleased to announce two important\n presentations. Donald McCaffrey will be presenting on Friday, April 20,\n 2012 at BioCentury Future Leaders in the Biotech Industry in New York,\n NY.  On April 21, 2012, Drs. Norman Wong and Peter Young will be\n presenting at the ATVB HDL Workshop Meeting in Chicago, IL.\n\n\nAbout RVX-208\nRVX-208 is a novel small molecule that stimulates endogenous ApoA-I\n production to trigger the synthesis of HDL. The use of this approach\n will enhance the functionality of HDL. ApoA-I is the major protein\n component of HDL.  The main role of these particles is to act as the\n body's natural defense system against atherosclerosis by mediating a\n normal physiologic process called reverse cholesterol transport (RCT). \n This pathway enables cholesterol, including that within atherosclerotic\n plaques of vessel walls, to be transported to the liver for further\n processing and elimination from the body.  Enhanced RCT clearance of\n cholesterol from vessel walls is expected to reduce or prevent\n atherosclerosis. The ability of RVX-208 to increase ApoA-I production\n and thereby augment RCT differentiates it from other HDL therapies.\n RVX-208 is positioned to be one of the most promising drugs in\n development for the treatment of atherosclerosis...